Nisa Investment Advisors LLC Purchases 83,401 Shares of Bristol Myers Squibb Company $BMY

Nisa Investment Advisors LLC raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 19.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 505,910 shares of the biopharmaceutical company’s stock after buying an additional 83,401 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Bristol Myers Squibb were worth $22,817,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Gateway Investment Advisers LLC raised its stake in shares of Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after acquiring an additional 10,284 shares during the last quarter. Commonwealth Retirement Investments LLC increased its holdings in Bristol Myers Squibb by 24.6% during the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after purchasing an additional 11,690 shares in the last quarter. CWA Asset Management Group LLC increased its holdings in Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after purchasing an additional 30,909 shares in the last quarter. Norges Bank bought a new position in Bristol Myers Squibb in the 2nd quarter valued at $1,554,154,000. Finally, Wealth Quarterback LLC boosted its stake in Bristol Myers Squibb by 42.6% in the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company’s stock worth $1,178,000 after purchasing an additional 7,603 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY, citing improved fundamentals and/or valuation support from recent earnings and guidance — a boost for investor confidence and likely a contributor to buying interest. Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group
• Positive Sentiment: Piper Sandler reiterated a buy rating for BMY, reinforcing sell‑side support and reducing downside risk from analyst sentiment. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: BioNTech and Bristol Myers Squibb expanded a pancreatic cancer program with a new Phase II trial — clinical progress in a high‑need oncology indication improves long‑term upside potential if data are positive. BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial
• Positive Sentiment: BMY added a new immunotherapy combo in small‑cell lung cancer, broadening its oncology pipeline and potential label-expansion or combination opportunities. Pipeline depth tends to support premium multiples in pharma names. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Neutral Sentiment: Analyst/industry pieces (Argus, Yahoo valuation reviews, and a Zacks recap) note BMY’s recent share gains and evolving profitability story but raise valuation questions as shares have recovered — these provide context but no immediate directional trigger. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: CNBC preview of the JPMorgan Healthcare Conference highlights that the event could be a catalyst (pipeline updates, commercialization and M&A talk) for BMY, but outcomes depend on what management and peers announce. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Headline pieces summarizing recent developments (Yahoo/TipRanks recaps) provide useful investor reading but are largely descriptive rather than delivering a single market-moving event. How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story

Bristol Myers Squibb Price Performance

BMY opened at $55.92 on Friday. The company has a fifty day moving average price of $50.93 and a two-hundred day moving average price of $47.80. The firm has a market capitalization of $113.84 billion, a PE ratio of 18.89, a P/E/G ratio of 9.29 and a beta of 0.29. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the previous year, the firm earned $1.80 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 85.14%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Tuesday, December 23rd. Citigroup reissued a “neutral” rating and issued a $53.00 price target (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Wednesday. Morgan Stanley restated an “underweight” rating and issued a $37.00 price objective (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, Scotiabank reiterated a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday. Six investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $56.62.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.